Company news
Curasight A/s (NGM:CURAS) news
Curasight A/s news releases on 6ix. Latest, Jul 27, 2026: Curasight Announces protocol update for the Phase I uTREAT trial in Aggressive Brain Cancer…
Press releases & updates
Curasight Announces protocol update for the Phase I uTREAT trial in Aggressive Brain Cancer (Glioblastoma)
July 27, 2026
Curasight A/S has successfully completed a directed issue of shares of approximately DKK 20 million
June 22, 2026
Curasight A/S announces its intention to carry out a directed issue of shares
June 22, 2026
Curasight Announces Preliminary Readout from its Phase 1 Clinical Trial with uTREAT[®] in Aggressive Brain Cancer (Glioblastoma)
June 8, 2026
Curasight: Major Shareholding Notification - share transfer and ownership restructuring – related party transaction
April 26, 2026
Major Shareholding Notification - share transfer and ownership restructuring - related party transaction
April 26, 2026
Resolutions of the Annual General Meeting 2026 of Curasight A/S
March 25, 2026
Curasight: Notice of Annual General Meeting 2026
March 10, 2026
Curasight reduces debt through Fenja Capital conversion
March 9, 2026
Curasight reduces convertible debt as Fenja Capital converts and enters into a block trade
March 6, 2026
Curasight: Major Shareholding Notification
February 9, 2026
Major Shareholding Notification
February 9, 2026
Curasight Announces Encouraging Preliminary Data from Phase 1 Trial Evaluating First-in-Class Radiopharmaceutical uTREAT in High-Grade Gliomas®
January 12, 2026
Curasight to hold Meetings in San Francisco During J.P. Morgan Healthcare Conference Week
January 5, 2026
Curasight A/S resolves to issue a convertible loan note
December 29, 2025
Curasight Announces Successful Dosing of First Patient in Phase 1 trial with uTREAT® in Brain Cancer
December 18, 2025
Curasight announces acceptance of clinical trial application (CTA) for phase 1 trial with uTREAT® in brain cancer patients
August 26, 2025